Organon Reports Q3 2025 Revenue of $6.2 Billion to $6.25 Billion
Organon & Co. reported third quarter 2025 non-GAAP adjusted net income of $263 million, or $1.01 per diluted share, compared to $226 million, or $0.87 per diluted share, in the third quarter of 2024. Non-GAAP adjusted EBITDA margin rose to 32.3% from 29.0% year over year, primarily due to a 14% reduction in non-GAAP operating expenses. Full year 2025 revenue guidance was revised to $6.2 billion to $6.25 billion, down from the previous range of $6.3 billion to $6.4 billion. Nominal revenue growth is now expected between -3.2% and -2.4%. As of September 30, 2025, cash and cash equivalents totaled $672 million, and debt stood at $8.8 billion. The Board of Directors declared a quarterly dividend of $0.02 per share, payable December 11, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110058374) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.